Intraocular use of rituximab

A. S. Kitzmann; J. S. Pulido; B. G. Mohney; K. H. Baratz; T. Grube; R. J. Marler; M. J. Donaldson; B. P. O'Neill; P. B. Johnston; K. M. Johnson; L. E. Dixon; D. R. Salomao; J. D. Cameron

doi:10.1038/sj.eye.6702804

Intraocular use of rituximab

A. S. Kitzmann
, J. S. Pulido
, B. G. Mohney
, K. H. Baratz
, T. Grube
, R. J. Marler
, M. J. Donaldson
, B. P. O'Neill
, P. B. Johnston
, K. M. Johnson
, L. E. Dixon
, D. R. Salomao
, J. D. Cameron

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

Purpose: To evaluate the toxicity of 1 mg of intraocular rituximab and to present a small case-series of patients treated with intravitreal rituximab. Methods: Rituximab (1 mg/0.1 ml) was injected in the vitreous of one eye of three Dutch-belted rabbits. Two animals were injected with balanced salt solution as controls. At 1 month the rabbits were killed and the eyes examined by light microscopy. Three patients (five eyes) with intraocular lymphoma were also treated with a 1 mg injection of rituximab. Results: The treated rabbit eyes and the control eyes showed no light microscopic evidence of ocular toxicity at 1 month following injection. The five human eyes of three patients have shown no evidence of intraocular toxicity with a median follow-up time of 3.6 months (range 2.0-6.4 months). One patient received a total of four injections in the right eye and three injections in the left eye. Conclusion: Intravitreal rituximab at a dose of 1 mg does not appear to cause toxicity in rabbit eyes and in the five eyes of three patients.

Original language	English (US)
Pages (from-to)	1524-1527
Number of pages	4
Journal	Eye
Volume	21
Issue number	12
DOIs	https://doi.org/10.1038/sj.eye.6702804
State	Published - Dec 2007
Externally published	Yes

Bibliographical note

Funding Information:
This study was supported in part by an unrestricted grant from Research to Prevent Blindness Inc., NY. This paper was presented as a talk at the American Uveitis Society Annual Meeting, Fort Lauderdale, Florida, April 29, 2006. Conflict of interest: None of the authors have any proprietary interest in any aspect of this report.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1038/sj.eye.6702804

Find It

Find It at U of M Libraries

Cite this

@article{84036c48d3f443db97e2679f28b6e4ff,

title = "Intraocular use of rituximab",

abstract = "Purpose: To evaluate the toxicity of 1 mg of intraocular rituximab and to present a small case-series of patients treated with intravitreal rituximab. Methods: Rituximab (1 mg/0.1 ml) was injected in the vitreous of one eye of three Dutch-belted rabbits. Two animals were injected with balanced salt solution as controls. At 1 month the rabbits were killed and the eyes examined by light microscopy. Three patients (five eyes) with intraocular lymphoma were also treated with a 1 mg injection of rituximab. Results: The treated rabbit eyes and the control eyes showed no light microscopic evidence of ocular toxicity at 1 month following injection. The five human eyes of three patients have shown no evidence of intraocular toxicity with a median follow-up time of 3.6 months (range 2.0-6.4 months). One patient received a total of four injections in the right eye and three injections in the left eye. Conclusion: Intravitreal rituximab at a dose of 1 mg does not appear to cause toxicity in rabbit eyes and in the five eyes of three patients.",

author = "Kitzmann, \{A. S.\} and Pulido, \{J. S.\} and Mohney, \{B. G.\} and Baratz, \{K. H.\} and T. Grube and Marler, \{R. J.\} and Donaldson, \{M. J.\} and O'Neill, \{B. P.\} and Johnston, \{P. B.\} and Johnson, \{K. M.\} and Dixon, \{L. E.\} and Salomao, \{D. R.\} and Cameron, \{J. D.\}",

note = "Funding Information: This study was supported in part by an unrestricted grant from Research to Prevent Blindness Inc., NY. This paper was presented as a talk at the American Uveitis Society Annual Meeting, Fort Lauderdale, Florida, April 29, 2006. Conflict of interest: None of the authors have any proprietary interest in any aspect of this report.",

year = "2007",

month = dec,

doi = "10.1038/sj.eye.6702804",

language = "English (US)",

volume = "21",

pages = "1524--1527",

journal = "Eye",

issn = "0950-222X",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Intraocular use of rituximab

AU - Kitzmann, A. S.

AU - Pulido, J. S.

AU - Mohney, B. G.

AU - Baratz, K. H.

AU - Grube, T.

AU - Marler, R. J.

AU - Donaldson, M. J.

AU - O'Neill, B. P.

AU - Johnston, P. B.

AU - Johnson, K. M.

AU - Dixon, L. E.

AU - Salomao, D. R.

AU - Cameron, J. D.

N1 - Funding Information: This study was supported in part by an unrestricted grant from Research to Prevent Blindness Inc., NY. This paper was presented as a talk at the American Uveitis Society Annual Meeting, Fort Lauderdale, Florida, April 29, 2006. Conflict of interest: None of the authors have any proprietary interest in any aspect of this report.

PY - 2007/12

Y1 - 2007/12

N2 - Purpose: To evaluate the toxicity of 1 mg of intraocular rituximab and to present a small case-series of patients treated with intravitreal rituximab. Methods: Rituximab (1 mg/0.1 ml) was injected in the vitreous of one eye of three Dutch-belted rabbits. Two animals were injected with balanced salt solution as controls. At 1 month the rabbits were killed and the eyes examined by light microscopy. Three patients (five eyes) with intraocular lymphoma were also treated with a 1 mg injection of rituximab. Results: The treated rabbit eyes and the control eyes showed no light microscopic evidence of ocular toxicity at 1 month following injection. The five human eyes of three patients have shown no evidence of intraocular toxicity with a median follow-up time of 3.6 months (range 2.0-6.4 months). One patient received a total of four injections in the right eye and three injections in the left eye. Conclusion: Intravitreal rituximab at a dose of 1 mg does not appear to cause toxicity in rabbit eyes and in the five eyes of three patients.

AB - Purpose: To evaluate the toxicity of 1 mg of intraocular rituximab and to present a small case-series of patients treated with intravitreal rituximab. Methods: Rituximab (1 mg/0.1 ml) was injected in the vitreous of one eye of three Dutch-belted rabbits. Two animals were injected with balanced salt solution as controls. At 1 month the rabbits were killed and the eyes examined by light microscopy. Three patients (five eyes) with intraocular lymphoma were also treated with a 1 mg injection of rituximab. Results: The treated rabbit eyes and the control eyes showed no light microscopic evidence of ocular toxicity at 1 month following injection. The five human eyes of three patients have shown no evidence of intraocular toxicity with a median follow-up time of 3.6 months (range 2.0-6.4 months). One patient received a total of four injections in the right eye and three injections in the left eye. Conclusion: Intravitreal rituximab at a dose of 1 mg does not appear to cause toxicity in rabbit eyes and in the five eyes of three patients.

UR - https://www.scopus.com/pages/publications/37749034029

UR - https://www.scopus.com/pages/publications/37749034029#tab=citedBy

U2 - 10.1038/sj.eye.6702804

DO - 10.1038/sj.eye.6702804

M3 - Article

C2 - 17464308

AN - SCOPUS:37749034029

SN - 0950-222X

VL - 21

SP - 1524

EP - 1527

JO - Eye

JF - Eye

IS - 12

ER -

Intraocular use of rituximab

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this